APA (7th ed.) Citation

McElroy, M. C., Kirton, C., Gliddon, D., & Wolff, R. K. (2013). Inhaled biopharmaceutical drug development: Nonclinical considerations and case studies. Inhalation Toxicology, 25(4), 219. https://doi.org/10.3109/08958378.2013.769037

Chicago Style (17th ed.) Citation

McElroy, Mary C., Chris Kirton, Dan Gliddon, and Ron K. Wolff. "Inhaled Biopharmaceutical Drug Development: Nonclinical Considerations and Case Studies." Inhalation Toxicology 25, no. 4 (2013): 219. https://doi.org/10.3109/08958378.2013.769037.

MLA (9th ed.) Citation

McElroy, Mary C., et al. "Inhaled Biopharmaceutical Drug Development: Nonclinical Considerations and Case Studies." Inhalation Toxicology, vol. 25, no. 4, 2013, p. 219, https://doi.org/10.3109/08958378.2013.769037.